We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Response to Varicella-Zoster Vaccination and Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00921999
Recruitment Status : Completed
First Posted : June 17, 2009
Last Update Posted : October 6, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Background:

  • The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease.
  • By drawing and studying blood samples from people who have been infected with the varicella-zoster virus or who are receiving or have received the varicella vaccine, researchers hope to learn more about the immune system s response to the virus.

Objectives:

- To determine the immune system s response to the varicella virus, either in its existing form or given as part of a vaccine.

Eligibility:

  • Individuals 18 years of age and older who have had or are receiving the varicella vaccine.
  • Individuals 5 years of age and older who currently have chickenpox or shingles.

Design:

  • Participants will visit the NIH Clinical Center for an initial physical examination, and will provide blood samples for evaluation.
  • Researchers will determine the number of samples to be taken and the amount of blood to be drawn as needed based on the participants medical history and exposure to the varicella-zoster virus.

Investigators in this study will not be giving subjects either the chickenpox or shingles vaccine. They will only be looking at the response to the vaccine in persons who are receiving or have received the vaccine from their health care provider.


Condition or disease
Chickenpox Herpes Zoster

Detailed Description:
Varicella-zoster virus (VZV) causes chickenpox (varicella) and shingles (zoster). Antibody is important for control of varicella as evidenced by the role of varicella immune globulin in limiting the severity of disease in immunocompromised persons. Limited information is available regarding the individual viral proteins to which antibodies are produced during primary infection with VZV or after vaccination. Furthermore, commercially available tests to determine seropositivity to VZV after vaccination have limited sensitivity, and improved assays are needed. We will obtain blood from persons with varicella, zoster, and those vaccinated with the varicella (not zoster) vaccine at the NIH Clinical Center and measure immune responses against specific viral proteins, look for virus in the blood, and in some cases measure immune responses against cellular proteins over time. Elucidation of these responses might help to develop more sensitive assays for VZV seropositivity after vaccination and determine how the varicella vaccine protects against varicella.

Study Design

Study Type : Observational
Actual Enrollment : 19 participants
Time Perspective: Prospective
Official Title: Immune Responses to Varicella-Zoster Virus Vaccination and Infection
Study Start Date : June 15, 2009
Estimated Study Completion Date : January 8, 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Chickenpox Shingles
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Group I Frequent Follow-up Group (N=110)

  1. 18 years of age or older
  2. Patients about to receive the varicella vaccine, or were vaccinated within the last 5 days (if stored blood is available).
  3. Both males and females
  4. Subjects must be able to sign the consent form and be willing to comply with study procedures.
  5. Subjects must be willing to have their blood samples stored.

Group II Infrequent Follow-up Group (N=30)

  1. 18 years of age of older
  2. Patient about to receive the varicella vaccine, or were vaccinated within the last 30 days (if stored blood is available).
  3. Both males and females
  4. Subjects must be able to sign the consent form and be willing to comply with study procedures.
  5. Subjects must be willing to have their blood samples stored.

Group III Vaccine Recipients-Vaccinated in the Past (N=60)

  1. 18 years of age or older
  2. Patients were vaccinated with varicella vaccine at least 6 months previously and must provide written documentation of varicella vaccination
  3. Both males and females
  4. Subjects must be able to sign the consent form and be willing to comply with study procedures.
  5. Subjects must be willing to have their blood samples stored.

Group IV Patients with Varicella or Zoster (N=110)

  1. 5 years or older<TAB>
  2. Patients presenting with varicella or zoster.
  3. Both males and females
  4. Subjects and/or parents/guardians must be able to sign the consent or assent form and be willing to comply with study procedures.
  5. Subjects must be willing to have their blood samples stored.

EXCLUSION CRITERIA:

Study subjects will be excluded if they fulfill either of the following criteria:

  1. Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise patient safety (Groups I, II, IV who will be providing several blood samples)
  2. History of chickenpox, zoster, or having received the zoster vaccine for patients in Groups I, II or III.
  3. Patients in group I found to have a hemoglobin <11 gm/dl will be reassigned to group II or terminated from the study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00921999


Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Principal Investigator: Jeffrey I Cohen, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00921999     History of Changes
Other Study ID Numbers: 090170
09-I-0170
First Posted: June 17, 2009    Key Record Dates
Last Update Posted: October 6, 2017
Last Verified: January 8, 2015

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Chickenpox
Shingles
Varicella
Zoster
Vaccine

Additional relevant MeSH terms:
Herpes Zoster
Chickenpox
Herpesviridae Infections
DNA Virus Infections
Virus Diseases